Hepatitis C virus and its cutaneous manifestations: treatment in the direct‐acting antiviral era

Wiznia, Lauren E.; Laird, Mary E.; Franks, Andrew G.

doi:10.1111/jdv.14186

Cited by 27 publications

(13 citation statements)

References 90 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct-acting antiviral (DAA) therapy achieves SVR rates over 90% and is currently recommended for patients with chronic HCV, based on the degree of liver fibrosis, HCV genotype, resistance variants, previous treatment failure and comorbidities [77,78]. The advantages of DAA over IFN-α and ribavirin therapy are an increased response rate and reduced length of therapy, i.e.…”

Section: Therapeutic Management Of Oral Lichen Planus In Patients Witmentioning

confidence: 99%

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Meşter

Lucaciu

Ciobanu

et al. 2018

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Oral lichen planus (OLP) is a chronic inflammatory disease characterized by the occurrence of multiple, symmetrical lesions in the oral cavity. Hepatitis C virus (HCV) infection has been suggested as an etiological factor in OLP. The purpose of this review was to summarize the current literature regarding the treatment of OLP in patients with HCV infection. An electronic search of the PubMed database was conducted until January 2018, using the following keywords: OLP, HCV, corticosteroids, retinoids, immunomodulatory agents, surgical interventions, photochemotherapy, laser therapy, interferon, ribavirin, and direct-acting antivirals. We selected the articles focusing on the clinical features and treatment management of OLP in patients with/without HCV infection. Topical corticosteroids are considered the first-line treatment in OLP. Calcineurin inhibitors or retinoids can be beneficial for recalcitrant OLP lesions. Systemic therapy should be used in the case of extensive and refractory lesions that involve extraoral sites. Surgical intervention is recommended for isolated lesions. In patients with HCV, monotherapy with interferon (IFN)-α may either improve, aggravate or trigger OLP lesions, while combined IFN-α and ribavirin therapy does not significantly influence the progression of lesions. Direct-acting antiviral (DAA) therapy appears to be a promising approach in patients with HCV-related OLP, as it can improve symptoms of both liver disease and OLP, with fewer side effects. Nevertheless, for clinical utility of DAAs in OLP patients, further studies with larger sample sizes, adequate treatment duration, and long term follow-up are required.

show abstract

Section: Therapeutic Management Of Oral Lichen Planus In Patients Witmentioning

confidence: 99%

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Meşter

Lucaciu

Ciobanu

et al. 2018

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…C hronic viral infections are an important worldwide health concern. Globally, approximately 240 million people are chronically infected with hepatitis B virus (HBV) 1 , more than 170 million are infected with hepatitis C virus (HCV) 2,3 , and 75 million are infected with human immunodeficiency virus (HIV) 4 . These viruses can lead to persistent infection and dysfunction of adaptive immunity 2,5 .…”

mentioning

confidence: 99%

CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection

Khairnar

Duhan

Patil³

et al. 2018

Nat Commun

View full text Add to dashboard Cite

Dysfunction of CD8+ T cells can lead to the development of chronic viral infection. Identifying mechanisms responsible for such T cell dysfunction is therefore of great importance to understand how to prevent persistent viral infection. Here we show using lymphocytic choriomeningitis virus (LCMV) infection that carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is fundamental for recruiting lymphocyte-specific protein kinase (Lck) into the T cell receptor complex to form an efficient immunological synapse. CEACAM1 is essential for activation of CD8+ T cells, and the absence of CEACAM1 on virus-specific CD8+ T cells limits the antiviral CD8+ T cell response. Treatment with anti-CEACAM1 antibody stabilizes Lck in the immunological synapse, prevents CD8+ T cell exhaustion, and improves control of virus infection in vivo. Treatment of human virus-specific CD8+ T cells with anti-CEACAM1 antibody similarly enhances their proliferation. We conclude that CEACAM1 is an important regulator of virus-specific CD8+ T cell functions in mice and humans and represents a promising therapeutic target for modulating CD8+ T cells.

show abstract

“…This second hypothesis was further supported after the publication of case reports associating the involution of OLP and other EHMs 23,24 to the SVR with the use of AAD, [25][26][27] including re-establishment of immune tolerance in the patients. [28][29][30] These findings make us to suggest that the ideal treatment for cases of HCV-associated OLP should be coupled with the establishment of SVR.…”

Section: Discussionmentioning

confidence: 99%

Oral lichen planus and HCV infection

Tenório¹,

Camargo²,

Lemos³

et al. 2020

Autops Case Rep

View full text Add to dashboard Cite

Hepatitis C virus and its cutaneous manifestations: treatment in the direct‐acting antiviral era

Cited by 27 publications

References 90 publications

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection

Oral lichen planus and HCV infection

Contact Info

Product

Resources

About